Suppr超能文献

酒精性肝硬化合并大量腹水患者的腹腔静脉分流术与药物治疗的比较。退伍军人管理局酒精性肝硬化腹水治疗合作研究。

Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites.

作者信息

Stanley M M, Ochi S, Lee K K, Nemchausky B A, Greenlee H B, Allen J I, Allen M J, Baum R A, Gadacz T R, Camara D S

机构信息

VA Medical Center, Hines, IL 60141.

出版信息

N Engl J Med. 1989 Dec 14;321(24):1632-8. doi: 10.1056/NEJM198912143212403.

Abstract

The optimal management of severe ascites in patients with alcoholic cirrhosis has not been defined. in a 5 1/2-year study, we randomly assigned 299 men with alcoholic cirrhosis, who had persistent or recurrent severe ascites despite a standard medical regimen, to receive either intensive medical treatment or peritoneovenous (LeVeen) shunting. We identified three risk groups: Group 1 had normal or mildly abnormal results on liver-function tests, Group 2 had more severe liver dysfunction or previous complications, and Group 3 had severe prerenal azotemia without kidney disease. For the patients who received the medical treatment and those who received the surgical treatment combined, the median survival times were 1093 days in Group 1, 222 days in Group 2, and 37 days in Group 3 (P less than or equal to 0.01) for all comparisons). For all the groups combined, the median time to the resolution of ascites was 5.4 weeks for medical patients and 3.0 weeks for surgical patients (P less than 0.01). Within each risk group, mortality during the initial hospitalization and median long-term survival were similar among patients receiving either treatment. However, the median time to the recurrence of ascites in Group 1 was 4 months in medical patients, as compared with 18 months in surgical patients (P = 0.01); in Group 2 it was 3 months in medical patients as compared with 12 months in surgical patients (P = 0.04). The median duration of hospitalization was longer in medical patients than in surgical patients (6.1 vs. 2.4 weeks in Group 1 [P less than 0.001] and 5.0 vs. 3.1 weeks in Group 2 [P less than 0.01]). Group 3 was too small to permit a meaningful comparison. During the initial hospitalization, the incidence of infections, gastrointestinal bleeding, and encephalopathy was similar among the medical and surgical patients. We conclude that peritoneovenous shunting alleviated disabling ascites more rapidly than medical management. However, survival was closely related to the severity of the illness at the time of randomization and was not altered by shunting.

摘要

酒精性肝硬化患者严重腹水的最佳治疗方法尚未明确。在一项为期5年半的研究中,我们将299名患有酒精性肝硬化的男性患者随机分组,这些患者尽管接受了标准药物治疗方案,但仍有持续性或复发性严重腹水,他们被分配接受强化药物治疗或腹腔静脉(LeVeen)分流术。我们确定了三个风险组:第1组肝功能检查结果正常或轻度异常;第2组肝功能障碍更严重或有既往并发症;第3组有严重的肾前性氮质血症但无肾脏疾病。对于接受药物治疗和手术治疗的患者,所有比较中,第1组的中位生存时间为1093天,第2组为222天,第3组为37天(P≤0.01)。对于所有组的患者,药物治疗组腹水消退的中位时间为5.4周,手术治疗组为3.0周(P<0.01)。在每个风险组内,接受任何一种治疗的患者在初次住院期间的死亡率和中位长期生存率相似。然而,第1组中,药物治疗患者腹水复发的中位时间为4个月,而手术治疗患者为18个月(P = 0.01);第2组中,药物治疗患者为3个月,手术治疗患者为12个月(P = 0.04)。药物治疗患者的中位住院时间比手术治疗患者长(第1组中分别为6.1周和2.4周[P<0.001],第2组中分别为5.0周和3.1周[P<0.01])。第3组样本量太小,无法进行有意义的比较。在初次住院期间,药物治疗患者和手术治疗患者的感染、胃肠道出血和脑病发生率相似。我们得出结论,腹腔静脉分流术比药物治疗能更快地缓解致残性腹水。然而,生存率与随机分组时疾病的严重程度密切相关,分流术并未改变生存率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验